Active Biotech Ab

Pharmacia Ab

Per Antonsson

Mikael Dohlsten

Terje Kalland

Bjorn Ulrik Walse

Eva Erlandsson

Johan Hansson

Lars B Abrahmsen

Göran Forsberg

Per Bjork

Lars Abrahms&eacute;n

Per Axel Bj&ouml;rk

G&ouml;ran Forsberg

The present invention relates to compositions and methods of use, wherein the composition comprises a conjugate of a bacterial superantigen and an antibody moiety. More particularly, the bacterial superantigen has been modified to decrease seroreactivity with retained superantigen activity.

Methods for treating a subject having cancer by the administration of a conjugate between a variant staphylococcal entertoxin E superantigen and an antibody that binds to the 5T4 antigen

A conjugate between a target-seeking moiety and a modified superantigen, characterized in that the superantigen is a wild-type superantigen (SA I) in which an amino acid residue in a superantigen region (region I) determining binding to TCR, preferably TCRV&#x3b2;, and T cell activation have been replaced by another amino acid residue while retaining the ability to activate a subset of T cells. In preferred embodiment the modified superantigen is a chimer between at least two wild-type superantigens (SA I, SA II etc) characterized in that one or more amino acid residues in a region determining binding to TCR and T cell activation have been interchanged between various wild-type superantigens. A therapeutic method making use of modified/chimeric superantigens as defined in the preceding paragraphs. An antibody preparation in which the cysteine residues that provide for interchain disulfide bonds have been mutated so as to forbid interchain disulfide bridges, preferably to serine residues, for use as pharmaceutical.

Modified Chimeric superantigens and their use

Engineered superantigen for human therapy

Modified/chimeric superantigens and their use

Growing community of inventors

Lund, Sweden

Per Antonsson